40 results about "Biomarker Analysis" patented technology

Continuing a sequence of lensless light-field imaging camera patents beginning 1999, the present invention adds light-use efficiency, predictive-model design, distance-parameterized interpolation, computational efficiency, arbitrary shaped surface-of-focus, angular diversity / redundancy, distributed image sensing, plasmon surface propagation, and other fundamentally enabling features. Embodiments can be fabricated entirely by printing, transparent / semi-transparent, layered, of arbitrary size / curvature, flexible / bendable, emit light, focus and self-illuminate at zero-separation distance between (planar or curved) sensing and observed surfaces, robust against damage / occulation, implement color sensing without use of filters or diffraction, overlay on provided surfaces, provided color and enhanced multi-wavelength color sensing, wavelength-selective imaging of near-infrared / near-ultraviolet, and comprise many other fundamentally enabling features. Embodiments can be thinner, larger / smaller, more light-use efficient, and higher-performance than recently-popularized coded aperture imaging cameras. Vast ranges of diverse previously-impossible applications are enabled: credit-card cameras / phones, in-body monitoring of healing / disease, advanced biomarker analysis systems, perfect eye-contact video conferencing, seeing fabrics / skin / housings, and manufacturing-monitoring, wear-monitoring, and machine vision capabilities.

An embodiment of the claimed invention is directed to a method that greatly streamlines and reduces costs for tissue preparation, preservation, long-term storage and sample retrieval for molecular analysis using a method based on dried blood spot (DBS) technology. In this method, a small needle punch sample of freshly excised tissue will be homogenized in stabilizing reagent and inserted into a device containing absorbent material and drying agent. This device is suitable for long-term sample storage at ambient temperature and allows for easy removal of sections for biomarker analysis.

The present invention is related to a method and kit (or device) for the detection and / or the quantification of biomarkers related to tumourigenesis. Said method is advantageously used to propose or adapt an anti-tumoural therapeutic protocol to be administered to a subject. Furthermore, said method and kit (or device) are a technical platform for the identification of new compounds, which are preferably used at (a) specific step(s) of an anti-tumoural therapeutic protocol.

The present invention relates generally to the field of biomarker analysis, particularly determining gene expression signatures from urine samples. The disclosure provides compositions, kits and methods for diagnosing a prostate disorder such as prostate cancer in a male subject.

A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from plasma samples with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyzes of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed as a non-invasive alternative to the conventional biopsy and immunohistochemistry. Detection of ovarian cancer also is assessed. The microfluidic chip, which may be fabricated of a glass substrate and a layer of poly(dimethylsiloxane), includes a serpentine microchannel to mix a fluid and a microchamber for the collection and detection of exosomes.

Provided herein are devices, systems, kits and methods for predicting or determining the gender of a fetus using cell free fetal nucleic acids in a small amount of maternal biological sample. Devices can be used at point of need during early stages of pregnancy and are compatible with communication devices.

The invention provides a biomarker analysis method based on multiple immunohistochemical techniques and its application. Among them, the biomarker analysis method uses the histological morphology, cell phenotype and corresponding spatial coordinate information of tumor tissue samples in the image recognition system, and compares the two biomarkers through the double positive cell score and the relative distance ratio of tumor-immune suppression. Automated analysis of the tumor immune microenvironment. The present invention also provides devices and devices for implementing the method, as well as corresponding computer-readable media. The invention can more accurately and efficiently characterize the spatial connection state of the tumor immune microenvironment, so that the relevant indicators of the tumor immune microenvironment can more effectively evaluate the curative effect of immunotherapy, and meet the requirements of multiple immunohistochemical techniques in clinical pathological work and scientific research. The need for tumor immune microenvironment analysis.

The invention provides a paper-based device based on mobile valve and molecular imprinting technology and its manufacturing method and application, characterized in that the manufacturing method includes the following steps: pattern design, chip original manufacturing, and electrode construction on the paper base , chip original connection, synthesizing a functionalized molecularly imprinted polymer layer, electrochemical polymerization, and eluting template molecules; the device is used for the analysis and detection of biomarkers in serum samples. The beneficial effect of the present invention is that: the invention provides a paper-based device based on mobile valve and molecular imprinting technology and its production method and application, and provides a brand-new device for clinical detection of biomarkers. Synthesized biomarker molecularly imprinted polymers, formed a set of clinical application methods, created a new strategy for antibody-free biomarker analysis, and realized the entire process from device fabrication to test result output on a paper-based device, which is economical , portable, fast and other advantages.

A cryogenic biopsy device is configured to provide thin, frozen tissue samples, which may be viewed under a microscope and selected for biomarker analysis. The device is configured to provide slices which are less than 50 micrometers in thickness, while snap-freezing the tissue and maintaining the sample in a deep-frozen state until it reaches the pathology lab for further processing. Alternatively, thicker slices can be harvested by the device and additional sectioning can be done in the pathology lab by using cryomicrotome. The device of the present invention may be used in rigid instruments and in flexible devices, such as endoscopes, for example, and may be suitable for single use or multiple use.

The present invention recognizes that current clinical laboratory testing methods for multiparametric single cell analysis are limited to analysis of intact live cells, and are insufficient for identification of signaling activation profile defining certain cell types, including but not limited to neoplastic and immunologically activated cell subsets. One aspect of the present invention generally relates to marker selection in panels to include proteins routinely assessed in standard FCM, while preferably also incorporating markers for surface receptor proteins within activated signaling cascades. A further aspect of the present invention generally relates to panel design for the following indications in neoplastic and non-neoplastic clinical applications as examples of the technology: (a) identification of CML progenitor cell subsets in the setting of disease recurrence after treatment discontinuation or relapse due to treatment resistance, and (b) characterization of activated basophils to predict the severity of an allergic response. Another aspect of the present invention generally relates to methods to measure levels of surface and IC biomarkers in separate or combined assays for robust characterization of each or select cell compartment, and data analysis based on results from each or all method(s) used for optimal detection of the markers. A further aspect of the present invention generally relates to the identification and profiling of cell subpopulations based on analysis of surface markers including those associated with lineage and maturation of cell types and receptor proteins, and the corresponding IC phosphoproteins including those in activated signaling cascades to predict certain disease states or response to treatment.